thumbnail image
  • Company
  • Pipeline
  • News & Events
  • Careers
  • Contact
  • Company
  • Pipeline
  • News & Events
  • Careers
  • Contact
    • Pharmaceuticals discovered with AI

    • EFFICIENT DRUG DISCOVERY & DEVELOPMENT

      twoXAR Pharmaceuticals is a drug discovery and development company focused on first-in-class small molecules. The company currently has a development portfolio of over 18 diseases. twoXAR saves years in drug development while generating a 30x hit rate at in vivo efficacy milestones over traditional methods.

    • OUR PIPELINE
    • WEBINAR SERIES

      Part 1: SVP R&D, Mark Eller discusses the role of AI in the drug discovery ecosystem

      Part 2: VP Discovery, Aaron Daugherty shares how we collaborate with our partners

      Part 3: SVP Nonclinical R&D & Chemistry, Anjali Pandey provides insight on what's next for twoXAR

      LATEST NEWS

      twoXAR Pharmaceuticals Presents Preclinical Data Demonstrating Positive Safety and Tolerability of Two Novel NASH Treatment Candidates

      November 13, 2020

      Why twoXAR Pharmaceuticals isn't working on COVID-19

      Andrew Radin

      October 28, 2020

      Will COVID-19 be the straw that breaks AI's back?

      Andrew Radin

      MedCity News

      October 21, 2020

      LATEST EVENTS

      Biotech Showcase

      (Digital)

      January 11-15, 2021

      twoXAR Pharmaceuticals CEO Andrew Radin presents on the company's capabilities in discovering first-in-class small molecules.

      Using Artificial Intelligence in Drug Discovery

      CM Life Sciences (Digital)

      December 3, 2020

      twoXAR Pharmaceuticals CEO Andrew A. Radin joins a webinar hosted by CM Life Sciences to discuss harnessing AI in drug discovery.

      EPPIC Global Presents: Role of AI/ML in transforming and accelerating the drug discovery process

      EPPIC Global (Digital)

      October 17, 2020

      twoXAR Pharmaceuticals SVP Nonclinical R&D & Chemistry Anjali Pandey moderates a panel including twoXAR CEO Andrew Radin, along with representatives from Recursion Pharma, ATOM Consortium, and NuMedii.

      NEWS & EVENTS

    © 2020 twoXAR, Incorporated | All Rights Reserved

      Home
      Pipeline
      News
      Contact
    Cookie Use
    We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.
    Learn More